World Journal of Nuclear Medicine

LETTER TO EDITOR
Year
: 2014  |  Volume : 13  |  Issue : 3  |  Page : 209-

Bone metastases treatment by Sm-153 oxabifore in combination with monoclonal antibody denosumab (Xgeva)


Beuy Joob1, Viroj Wiwanitkit2,  
1 Department of Medical Center, Sanitation 1 Medical Academic Center, Bangkok, Thailand
2 Department of Tropical Medicine, Joseph Ayo Babalola University, Osun State, Nigeria

Correspondence Address:




How to cite this article:
Joob B, Wiwanitkit V. Bone metastases treatment by Sm-153 oxabifore in combination with monoclonal antibody denosumab (Xgeva).World J Nucl Med 2014;13:209-209


How to cite this URL:
Joob B, Wiwanitkit V. Bone metastases treatment by Sm-153 oxabifore in combination with monoclonal antibody denosumab (Xgeva). World J Nucl Med [serial online] 2014 [cited 2022 Jan 22 ];13:209-209
Available from: http://www.wjnm.org/text.asp?2014/13/3/209/144825


Full Text

To the Editor,

A recent report on "bone metastases treatment by samarium (sm)-153 oxabifore in combination with monoclonal antibody denosumab (Xgeva)" is very interesting. [1] Rasulova et al. noted that "combined treatment of bone metastases with sm-153 oxabifore and denosumab is effective and safe. [1]" In fact, the combination is very interesting. A similar observation was also reported by Rasulova et al. on another combination between sm-153 oxabifore and bisphosphonate. Focusing on the present combination, sm-153 oxabifore and denosumab, the issue of side-effect should be studied in a larger scale. In fact, denosumab is generally used for management of bone loss in cancer patients. [2] However, some interesting side-effect of this drug can be seen. The important condition is osteonecrosis. [3],[4] For sm-153, the effectiveness and side-effect is still inconclusive. The flare up of pain can be possible during therapy. As already note, further studies are still required for conclusion (see a clinical report in Russian language: base.ukgma.kz/vestnik/2012/vestnik_3_12.doc).

References

1Rasulova N, Lyubshin V, Arybzhanov D, Krylov V, Khodjibekov M. Effectiveness of bone metastases treatment by sm-153 oxabifore in combination with monoclonal antibody denosumab (xgeva): First experience. World J Nucl Med 2013;12:19-23.
2Rasulova N, Lyubshin V, Arybzhanov D, Sagdullaev Sh, Krylov V, Khodjibekov M. Optimal timing of bisphosphonate administration in combination with samarium-153 oxabifore in the treatment of painful metastatic bone disease. World J Nucl Med 2013;12:14-8.
3Yee AJ, Raje NS. Denosumab, a RANK ligand inhibitor, for the management of bone loss in cancer patients. Clin Interv Aging 2012;7:331-8.
4Aghaloo TL, Dry SM, Mallya S, Tetradis S. Stage 0 osteonecrosis of the jaw in a patient on denosumab. J Oral Maxillofac Surg 2014;72:702-16.